Bringing innovative technology and precision, for better outcomes in regenerative therapeutics.
Our patient-first approach drives the development of innovative, non-invasive tissue repair technologies, ensuring safe, effective, and personalized healing solutions for optimal patient outcomes.
We uphold the highest standards of quality and safety in our device manufacturing processes, adhering strictly to regulatory requirements and industry best practices. Our commitment ensures reliability.
We are committed to delivering comprehensive educational resources, specialized training, and ongoing support, equipping healthcare professionals with the expertise to optimize treatment protocols and patient outcomes.
We actively collaborate with healthcare experts, researchers, and institutions, fostering knowledge-sharing and innovation to drive the advancement, efficacy, and integration of autologous biologic therapies.
At EmCyte Corporation®, we are dedicated to advancing regenerative medicine through innovative technology that delivers precision and predictability in autologous biologic preparations. We aim to provide physicians and practitioners with quality solutions for optimal patient outcomes. Backed by a sound manufacturing infrastructure and a highly qualified team, we uphold the strictest standards in product development and performance. Our commitment extends beyond innovation as we strive to instill confidence in our customers by ensuring reliability, consistency, and excellence in every biologic preparation. We stand by our unwavering commitment to deliver the best-in-class solutions for patients.
We are committed to quality, innovation, and trust, empowering healthcare professionals with best-in-class regenerative therapies that enhance patient care and drive excellence in treatment outcomes.
To build a transformative regenerative care system that empowers patients with knowledge and confidence in their regenerative healthcare decisions while equipping physicians with tools to deliver the best treatment option for every patient.
We prioritize patient outcomes over profits, ensuring that every treatment enhances the patient experience throughout their recovery journey. We are committed to setting realistic expectations and delivering successful treatment outcomes, fostering trust and excellence in regenerative care.
What began as a passion for enhancing wound healing has evolved into a trusted leader in autologous regenerative therapeutics. For over two decades, we have built a reputation for delivering top-tier proprietary formulations of platelet-rich plasma, bone marrow stem cell and other tissue biologics, for enhance tissue repair.
Our clinical, educational, and product development teams are experts in their craft, ensuring the highest level of service and cutting-edge regenerative products.
A distinguished consortium of pioneering medical advisors, advancing the frontier of regenerative therapeutics through clinical expertise.
Contact us today and be part of a skilled, passionate group dedicated to exceptional regenerative care.
The Vanguard of Regenerative Innovation
Envisioning a Future of Optimized Healing 1999-2010
In the transformative landscape of regenerative medicine, EmCyte Corporation® emerged as a pioneering force, charting a path toward innovation and clinical excellence. Founded by Patrick Pennie, an esteemed open-heart critical care registered nurse and perfusionist, the company was born from more than a decade of research in autologous biologics. With deep expertise in blood management and conservation strategies, Mr. Pennie envisioned a future where regenerative therapies could be optimized to enhance healing and improve clinical outcomes.
Early Years of Development 2008-2018
The early years of EmCyte Corporation® were marked by groundbreaking advancements in small-volume platelet concentrating preparations, revolutionizing the efficiency and efficacy of platelet-rich plasma (PRP) therapies. The success of these biologic technologies soon led to a broader vision, integrating bone marrow and adipose-derived stem cell biologics into treatment regimens. This expansion introduced cell differentiation into the autologous biologic milieu, elevating the regenerative potential of EmCyte’s Corporation® solutions.
Responding to the Moment 2019 - Current
As regenerative medicine evolved, the demand for precise biologic formulations and clinical dose requirements became paramount. EmCyte® responded with the development of the PURE® SupraPhysiologic Concentrating Systems, a suite of sophisticated technologies designed to empower physicians with highly potent, customizable biologics. These innovations enabled healthcare providers to tailor therapies to individual patient needs, ensuring greater consistency and effectiveness in clinical applications.
A Vision Materialized 2008
What began as a concept rooted in clinical expertise has grown into a state-of-the-art, 50,000-square-foot facility in Fort Myers, Florida, a hub of biologic innovation, education, and advanced manufacturing. This facility serves as the foundation for EmCyte’s® commitment to scientific discovery and regenerative healthcare education. Equipped with class 6 cleanrooms, injection mold machines, CNC machines, and precision lasers, EmCyte’s® manufacturing division ensures that all its biologic technologies are produced in the USA, meeting the highest standards of quality.
Training & Education Center 2019
A nonprofit educational and training center dedicated to the advancement of regenerative medicine through physician education and hands-on training.
Clinical & Scientific Research
Biofyl Scientific Research is an independent state-of-the-art regenerative science laboratory dedicated to pioneering breakthroughs in cellular regeneration. Equipped with cutting-edge technology and advanced analytical platforms, our research delves deep into the fundamental mechanisms of regenerative cell components, unlocking their potential for transformative medical applications. .
Our property portfolio represents the pinnacle of innovation in regenerative biologics, encompassing proprietary technologies, advanced processing methodologies, and groundbreaking device designs.
CENTRIFUGE TUBE ASSEMBLY
DUAL PISTON CENTRIFUGE TUBE
BONE MARROW ASPIRATE COLLECTION SYSTEM
CENTRIFUGE TUBE ASSEMBLY
CENTRIFUGE TUBE ASSEMBLY AND METHOD OF USING THE SAME
CENTRIFUGE TUBE ASSEMBLY AND METHOD OF USING THE SAME
CENTRIFUGE TUBE ASSEMBLY FOR SEPARATING, CONCENTRATING AND ASPIRATING CONSTITUENTS OF A FLUID PRODUCT ABSTRACT
CENTRIFUGE TUBE ASSEMBLY FOR SEPARATING, CONCENTRATING AND ASPIRATING CONSTITUENTS OF A FLUID PRODUCT ABSTRACT
CENTRIFUGE TUBE ASSEMBLY FOR SEPARATING, CONCENTRATING AND ASPIRATING CONSTITUENTS OF A FLUID PRODUCT
EmCyte Corporation has achieved multiple FDA 510(k) clearances for its cutting-edge regenerative medical technologies, demonstrating a steadfast commitment to safety, efficacy, and regulatory excellence.
The GenesisCS Component Concentrating System is intended to be used in a clinical laboratory or intraoperatively at the point of care for ithe safe and rapid preparation of platelet poor plasma and platelet concentrate from a small sample of blood and for a preparation of a cell concentrate from bone marrow. The safety and effectiveness of this device for in vivo indications for use has not been established.
The GenesisCS Component Concentrating System is designed to be used for the safe and rapid preparation of autologous platelet rich plasma (PRP) from a small sample of blood at the patient's point of care. The PRP can be mixed with autograft and allograft bone prior to application to an orthopedic surgical site as deemed necessary by the clinical use requirements.
The Progenikine Concentrating System is used in medical procedures involving the harvesting and transferring of autologous adipose tissue. The Progenikine® Concentrating System is used for concentrating adipose tissue harvested with a legally marketed lipoplasty system. The Progenikine Concentrating System is intended for use in the following surgical specialties when the concentration of harvested adipose tissue is desired. Neurosurgery, Gastrointestinal Surgery, Urological Surgery, Plastic and Re-constructive Surgery, General Surgery, Orthopedic Surgery, Gynecological Surgery, Laparoscopic Surgery, Arthroscopic Surgery.
The PureBMC® SupraPhysiologic Concentrating System is intended to be used in a clinical laboratory or intraoperatively at the point of care for the safe and rapid preparation of platelet poor plasma and platelet concentrate from a small sample of blood and for a preparation of a cell concentrate from bone marrow. The safety and effectiveness of this device for in vivo indications for use has not been established.
The PurePRP® SupraPhysiologic Concentrating System is designed to be used for the safe and rapid preparation of autologous platelet rich plasma (PRP) from a small sample of blood at the patient's point of care. The PRP is mixed with autograft and allograft bone prior to application to an orthopedic surgical site to improve bone graft handling characteristics.
The SECQUIRE cell separator is designed for the safe and effective preparation of low volume platelet rich plasma, and platelet poor plasma at the point of care.